Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ixazomib
Drug ID BADD_D01223
Description Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ixazomib citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, ixazomib, after administration.
Indications and Usage Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Marketing Status Prescription
ATC Code L01XG03
DrugBank ID DB09570
KEGG ID D10130
MeSH ID C548400
PubChem ID 25183872
TTD Drug ID Not Available
NDC Product Code 63020-230; 63020-080; 63020-079; 63020-078; 63020-390; 63020-400
Synonyms ixazomib | MLN 9708 | MLN9708 | MLN-9708 | Ninlaro
Chemical Information
Molecular Formula C14H19BCl2N2O4
CAS Registry Number 1072833-77-2
SMILES B(C(CC(C)C)NC(=O)CNC(=O)C1=C(C=CC(=C1)Cl)Cl)(O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vision blurred17.17.01.010; 06.02.06.0070.002931%
Visual acuity reduced17.17.01.011; 06.02.03.0010.000533%
Visual impairment06.02.06.0080.002398%Not Available
Vomiting07.01.07.0030.019182%
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
Wheezing22.03.01.009--
White blood cell count decreased13.01.06.0120.005595%
Cardiotoxicity12.03.01.007; 02.01.01.0020.000533%Not Available
Hypoacusis04.02.01.0060.000799%
Peripheral swelling08.01.03.053; 02.05.04.0150.009324%Not Available
Balance disorder17.02.02.0070.003197%Not Available
Contusion24.07.06.001; 23.03.11.002; 15.03.01.008; 12.01.06.001--
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.000799%
Malignant neoplasm progression16.16.01.005--Not Available
Oesophageal rupture12.01.09.012; 07.04.05.0050.000533%Not Available
Haemorrhage24.07.01.002--Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.000533%Not Available
Cognitive disorder17.03.03.003; 19.21.02.001--
Gastrointestinal toxicity07.08.03.006; 12.03.01.019--Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Cardiac disorder02.01.01.003--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.000533%Not Available
Limb discomfort15.03.04.0140.000533%Not Available
Lung infection22.07.01.008; 11.01.09.0080.001066%
Partial seizures17.12.03.0100.000533%Not Available
Upper limb fracture15.08.03.018; 12.04.01.0180.000533%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.0490.000533%Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages